Diltiazem, cis-(+)-[N-Methyl-3H]-, 250µCi (9.25MBq)

Diltiazem is a nondihydropyridine (non-DHP) calcium channel blocker used to treat hypertension and arrythmia.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New Englａnd Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET847:

1. Rupniak, N.M.J., Boyce, S., Williams, A.R., Cook, G., Longmore, J., Seabrook, G.R., Caeser, M., Iversen, S.D. and Hill, R.G. (1993), Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. British Journal of Pharmacology, 110: 1607–1613.
2. Hans Schoemaker, Polyamines allosterically modulate [3H]nitrendipine binding to the voltage-sensitive calcium channel in rat brain, In European Journal of Pharmacology: Molecular Pharmacology, Volume 225, Issue 2, 1992, Pages 167-169.